ArticleCancers2025

Tazemetostat, a Selective EZH2 Inhibitor, in Combination with Pembrolizumab for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: A Phase 1 Trial.

Peter J Oppelt et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.